CA2416603A1 - Inhibition de la maturation et de la replication du virus de l'hepatite c - Google Patents

Inhibition de la maturation et de la replication du virus de l'hepatite c Download PDF

Info

Publication number
CA2416603A1
CA2416603A1 CA002416603A CA2416603A CA2416603A1 CA 2416603 A1 CA2416603 A1 CA 2416603A1 CA 002416603 A CA002416603 A CA 002416603A CA 2416603 A CA2416603 A CA 2416603A CA 2416603 A1 CA2416603 A1 CA 2416603A1
Authority
CA
Canada
Prior art keywords
hsp90
cleavage
hcv
processing
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002416603A
Other languages
English (en)
Inventor
Lloyd H. Waxman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2416603A1 publication Critical patent/CA2416603A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

L'invention concerne des procédés permettant d'inhiber la réplication et la maturation de HCV par ciblage d'une protéine de stress 90 (HSP90). HSP90 est une protéine chaperonne cellulaire dont on a découvert qu'elle constitue un facteur essentiel de l'auto-clivage de NS2/3. HSP90 peut être ciblée au moyen de composés inhibant la capacité de HSP90 à faciliter le clivage de NS2/3.
CA002416603A 2000-07-20 2001-07-16 Inhibition de la maturation et de la replication du virus de l'hepatite c Abandoned CA2416603A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21955000P 2000-07-20 2000-07-20
US60/219,550 2000-07-20
PCT/US2001/022335 WO2002007761A1 (fr) 2000-07-20 2001-07-16 Inhibition de la maturation et de la replication du virus de l'hepatite c

Publications (1)

Publication Number Publication Date
CA2416603A1 true CA2416603A1 (fr) 2003-01-31

Family

ID=22819717

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002416603A Abandoned CA2416603A1 (fr) 2000-07-20 2001-07-16 Inhibition de la maturation et de la replication du virus de l'hepatite c

Country Status (4)

Country Link
EP (1) EP1322325A4 (fr)
JP (1) JP2004504356A (fr)
CA (1) CA2416603A1 (fr)
WO (1) WO2002007761A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030046397A (ko) * 2000-07-28 2003-06-12 슬로안-케테링인스티튜트퍼캔서리서치 세포증식성 질환 및 바이러스 감염의 치료 방법
MY148123A (en) 2003-09-05 2013-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
DE10361944A1 (de) * 2003-12-31 2005-07-28 Viromics Gmbh Mittel zur Hemmung der Virusreplikation durch Regulation der Proteinfaltung
SI1719773T1 (sl) 2004-02-24 2009-08-31 Japan Tobacco Inc Kondenzirane heterotetraciklične spojine in njihova uporaba kot inhibitorji polimeraze HCV
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
DE102004049078A1 (de) 2004-10-08 2006-04-13 Merck Patent Gmbh Phenylpyrazole
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
DE102005009440A1 (de) 2005-03-02 2006-09-07 Merck Patent Gmbh Thienopyridinderivate
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
WO2007058384A1 (fr) * 2005-11-17 2007-05-24 Osaka University Procede d'inhibition de la replication du virus de l'hepatite c, inhibiteur de replication du virus et procede de selection de cet inhibiteur
JP2007238442A (ja) * 2006-02-07 2007-09-20 Hiroshi Takaku 抗ウイルス剤
US8017612B2 (en) 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
DE102006030479A1 (de) 2006-07-01 2008-03-20 Merck Patent Gmbh Indazolderivate
DE102007002715A1 (de) 2007-01-18 2008-07-24 Merck Patent Gmbh Triazolderivat
DE102007028521A1 (de) 2007-06-21 2008-12-24 Merck Patent Gmbh Indazolamidderivate
DE102007032739A1 (de) 2007-07-13 2009-01-15 Merck Patent Gmbh Chinazolinamidderivate
DE102007041116A1 (de) 2007-08-30 2009-03-05 Merck Patent Gmbh 1,3-Dihydro-isoindolderivate
US9149463B2 (en) 2007-09-18 2015-10-06 The Board Of Trustees Of The Leland Standford Junior University Methods and compositions of treating a Flaviviridae family viral infection
US9101628B2 (en) 2007-09-18 2015-08-11 The Board Of Trustees Of The Leland Stanford Junior University Methods and composition of treating a flaviviridae family viral infection
US8940730B2 (en) 2007-09-18 2015-01-27 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions of treating a Flaviviridae family viral infection
AU2008302295B2 (en) 2007-09-18 2013-11-28 Stanford University Methods of treating a flaviviridae family viral infection and compositions for treating a flaviviridae family viral infection
DE102008061214A1 (de) 2008-12-09 2010-06-10 Merck Patent Gmbh Chinazolinamidderivate
CN102448457B (zh) * 2009-03-18 2015-09-02 小利兰·斯坦福大学理事会 治疗黄病毒科病毒感染的方法和组合物
WO2010107739A2 (fr) 2009-03-18 2010-09-23 The Board Of Trustees Of The Leland Stanford Junior University Méthodes et compositions pour traiter l'infection par un virus de la famille des flaviviridae
DE102009054302A1 (de) 2009-11-23 2011-05-26 Merck Patent Gmbh Chinazolinderivate
DE102010046837A1 (de) 2010-09-29 2012-03-29 Merck Patent Gmbh Phenylchinazolinderivate

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837251A (en) * 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
CN1099870C (zh) * 1997-01-28 2003-01-29 陶佩珍 格尔德霉素在制备新型广谱抗病毒药物中的用途

Also Published As

Publication number Publication date
JP2004504356A (ja) 2004-02-12
WO2002007761A1 (fr) 2002-01-31
EP1322325A4 (fr) 2004-09-15
EP1322325A1 (fr) 2003-07-02

Similar Documents

Publication Publication Date Title
CA2416603A1 (fr) Inhibition de la maturation et de la replication du virus de l'hepatite c
Shiryaev et al. Characterization of the Zika virus two-component NS2B-NS3 protease and structure-assisted identification of allosteric small-molecule antagonists
CN111886008B (zh) 用于抗mers-冠状病毒治疗的组合物和方法
CA3180177A1 (fr) Inhibiteurs de protease pour le traitement ou la prevention d'une maladie a coronavirus
Burnett et al. Herpes simplex virus-1 disarms the unfolded protein response in the early stages of infection
Lee et al. The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein
Jaeschke et al. Protection against TNF-induced liver parenchymal cell apoptosis during endotoxemia by a novel caspase inhibitor in mice
US20090203770A1 (en) COMPOSITIONS AND METHODS FOR MODULATING APOPTOSIS IN CELLS OVER-EXPRESSING Bcl-2 FAMILY MEMBER PROTEINS
US8187874B2 (en) Drug discovery method
Borowski et al. Non‐Structural Protein 3 of Hepatitis C Virus Inhibits Phosphorylation Mediated by cAMP‐Dependent Protein Kinase
US7241804B1 (en) Compositions and methods for modulating apoptosis in cells over-expressing Bcl-2 family member proteins
TW200528472A (en) Inhibitors of serine proteases, particularly HCV ns3-ns4a protease
KR20000075983A (ko) 헤파타이티스 ｃ 바이러스 복제를 선택적으로 저해하는 물질을 확인하기 위한 새로운 스크리닝 방법
TW201300108A (zh) Ｃ型肝炎病毒（ｈｃｖ）ｎｓ３-ｎｓ４ａ蛋白酶抑制劑
WO2000024725A1 (fr) Composes pentacycliques utiles en tant qu'inhibiteurs de l'helicase de ns3 du virus de l'hepatite c
Koka et al. Podocyte NLRP3 inflammasome activation and formation by adipokine visfatin
US6080791A (en) Method of treating a viral condition by inhibiting membrane fusion
EP3738603A1 (fr) Inhibiteur de ntcp
Pászti-Gere et al. In vitro interaction of potential antiviral TMPRSS2 inhibitors with human serum albumin and cytochrome P 450 isoenzymes
US20030211469A1 (en) Inhibiting hepatitis c virus processing and replication
Ciccaglione et al. The transmembrane domain of hepatitis C virus E1 glycoprotein induces cell death
Allen et al. Inhibitors of signal peptide peptidase (SPP) affect HSV-1 infectivity in vitro and in vivo
Moghadasi et al. Gain-of-function assay for SARS-CoV-2 Mpro inhibition in living cells
WO2001016379A1 (fr) Inhibiteurs de replication du virus de l'hepatite c
WO2021155798A1 (fr) Utilisation d'un polypeptide immun dans un médicament antiviral

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued